358 related articles for article (PubMed ID: 16441623)
21. [Antimycotic therapy of Tinea pedis and other foot mycoses].
Stock I
Med Monatsschr Pharm; 2008 Jul; 31(7):247-56; quiz 257-8. PubMed ID: 18808073
[TBL] [Abstract][Full Text] [Related]
22. Clinico-mycological study of dermatophytic infections and their sensitivity to antifungal drugs in a tertiary care center.
Mahajan S; Tilak R; Kaushal SK; Mishra RN; Pandey SS
Indian J Dermatol Venereol Leprol; 2017; 83(4):436-440. PubMed ID: 28540871
[TBL] [Abstract][Full Text] [Related]
23. Widespread, chronic, and fluconazole-resistant Trichophyton rubrum infection in an immunocompetent patient.
Balci DD; Cetin M
Mycoses; 2008 Nov; 51(6):546-8. PubMed ID: 18422918
[TBL] [Abstract][Full Text] [Related]
24. Species distribution and antifungal susceptibilities of dermatophytes during a one year period at a university hospital in Turkey.
Ozkutuk A; Ergon C; Yulug N
Mycoses; 2007 Mar; 50(2):125-9. PubMed ID: 17305776
[TBL] [Abstract][Full Text] [Related]
25. Antifungal susceptibility and genetic similarity of sequential isolates of Trichophyton rubrum from an immunocompetent patient with chronic dermatophytosis.
Cordeiro RA; Brilhante RS; Rocha MF; Rabenhorsch SH; Moreira JL; Grangeiro TB; Sidrim JJ
Clin Exp Dermatol; 2006 Jan; 31(1):122-4. PubMed ID: 16309501
[TBL] [Abstract][Full Text] [Related]
26. [Clinical study of itraconazole for the treatment of Tinea cruris, Tinea corporis and Tinea pedis interdigital].
Zaitz C; Ruiz LR; Drullis EM; Gurfinkel P; Ciarnuto MA
Rev Inst Med Trop Sao Paulo; 1990; 32(4):299-303. PubMed ID: 1966257
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey.
Oz Y; Qoraan I; Oz A; Balta I
Int J Dermatol; 2017 Jan; 56(1):68-74. PubMed ID: 27667305
[TBL] [Abstract][Full Text] [Related]
28. [Fundamental and clinical studies on the efficacy of bifonazole in patients with tinea pedis at 10 years after approval. Part 2. Clinical evaluation].
Watanabe S; Takahashi H; Nakamura Y; Nakamura E; Nishiyama Y; Teduka M; Yamaguchi H; Uchida K; Tomizawa T; Shimozuma M; Osada A; Kawano S; Nakauchi Y; Wakukawa M; Goto A; Ueda Y; Matsukawa A; Minami H; Arikawa J; Soma Y; Chi HI; Tamaki K
Jpn J Antibiot; 1996 Dec; 49(12):1095-108. PubMed ID: 9032596
[TBL] [Abstract][Full Text] [Related]
29. Molecular typing and antifungal susceptibility of Trichophyton rubrum isolates from patients with onychomycosis pre- and post-treatment.
de Assis Santos D; de Carvalho Araújo RA; Kohler LM; Machado-Pinto J; Hamdan JS; Cisalpino PS
Int J Antimicrob Agents; 2007 May; 29(5):563-9. PubMed ID: 17331707
[TBL] [Abstract][Full Text] [Related]
30. A study of dermatophytes and their in-vitro antifungal sensitivity.
Sumana MN; Rajagopal V
Indian J Pathol Microbiol; 2002 Apr; 45(2):169-72. PubMed ID: 12696733
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of broth microdilution antifungal susceptibility testing conditions for Trichophyton rubrum.
Santos DA; Hamdan JS
J Clin Microbiol; 2005 Apr; 43(4):1917-20. PubMed ID: 15815018
[TBL] [Abstract][Full Text] [Related]
32. Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period.
Comert F; Kulah C; Aktas E; Eroglu O; Ozlu N
Mycoses; 2007 Jan; 50(1):52-7. PubMed ID: 17302749
[TBL] [Abstract][Full Text] [Related]
33. Broad spectrum antidermatophytic drug for the control of tinea infection in human beings.
Bhadauria S; Kumar P
Mycoses; 2012 Jul; 55(4):339-43. PubMed ID: 21929713
[TBL] [Abstract][Full Text] [Related]
34. [Preclinical and clinical studies on the efficacy of bifonazole in patients with tinea pedis at 10 years after approval. Part 1. Susceptibility to bifonazole of clinical isolates of dermatophytes].
Yamaguchi H; Uchida K; Watanabe S; Takahashi H; Nakamura Y; Nakamura E; Nishiyama Y; Teduka M; Tomizawa T; Shimozuma M; Osada A; Kawano S; Nakauchi Y; Wakukawa M; Goto A; Ueda Y; Matsukawa A; Kubo M; Minami H; Arikawa J; Soma Y; Chi HI; Tamaki K
Jpn J Antibiot; 1996 Dec; 49(12):1085-94. PubMed ID: 9032595
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial.
Ghannoum MA; Wraith LA; Cai B; Nyirady J; Isham N
Br J Dermatol; 2008 Sep; 159(3):711-3. PubMed ID: 18510668
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete's foot): a randomized, double-blind, placebo-controlled study.
Ortonne JP; Korting HC; Viguié-Vallanet C; Larnier C; Savaluny E
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1307-13. PubMed ID: 17062050
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of the in vitro susceptibility pattern of clinical isolates of Trichophyton mentagrophytes and Trichophyton rubrum in Santiago, Chile].
Díaz Jarabrán MC; Díaz González P; Espinoza Rodríguez J; Carrillo Muñoz AJ
Rev Iberoam Micol; 2015; 32(2):83-7. PubMed ID: 24794211
[TBL] [Abstract][Full Text] [Related]
38. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
39. Treatment of tinea pedis with a single pulse of itraconazole.
Bonifaz A; Saúl A
Eur J Dermatol; 2002; 12(2):157-9. PubMed ID: 11872413
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology of superficial mycosis (tinea pedis, onychomycosis) in elementary school children in Istanbul, Turkey.
Hapcioglu B; Yegenoglu Y; Disci R; Erturan Z; Kaymakcalan H
Coll Antropol; 2006 Mar; 30(1):119-24. PubMed ID: 16617585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
